Healthcare services provider UDG Healthcare booked a steep fall in annual profit, owing to a loss booked on the sale of pharmaceutical products distributor Aquilant.
Pre-tax profit for the year through September slumped to $8.4m, down from $92.8m on-year.
Revenue from continuing operations rose 8% to $1.32bn, while adjusted profit rose 17% to $138.8m.
UDG Healthcare declared an interim dividend of 16p per share, up 20% on-year.
'Looking ahead to 2019, we expect continued progress, both organically and through further strategic acquisitions,' chief executive Brendan McAtamney said.
'We expect good underlying profit growth in both Ashfield Communications & Advisory and Sharp, particularly in the US.'
'In Ashfield Commercial & Clinical we will continue to diversify and differentiate our service offering, although in the short term we expect there to be some ongoing softness.'
'As we have done in previous years we will also continue to invest in our talent, systems and infrastructure, to ensure we continue to have an effective platform for future sustainable growth.'